Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Ovarian Neoplasms

Free Subscription Articles published in Oncogene Retrieve available abstracts of 46 articles: HTML format

Single Articles

January 2026
1. SUN J, Cai X, Yung MMH, Zhou W, et al
   Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
   Oncogene. 2026 Jan 16. doi: 10.1038/s41388-026-03676.
   PubMed    
   
   
   December 2025
2. JI F, Yan K, Ding B, Zhu Y, et al
   Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.
   Oncogene. 2025 Dec 17. doi: 10.1038/s41388-025-03663.
   PubMed     Abstract available
   
   
   
3. LI Q, Zhang S, Wang M, Yi Q, et al
   Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
   Oncogene. 2025 Dec 5. doi: 10.1038/s41388-025-03656.
   PubMed    
   
   
   November 2025
4. LIU S, He Y, Ning X, Xu W, et al
   SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
   Oncogene. 2025 Nov 28. doi: 10.1038/s41388-025-03584.
   PubMed     Abstract available
   
   
   October 2025
5. TANG S, Chen K, Zheng F, Fu Z, et al
   High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-kappaB1 pathway in epithelial ovarian cancer.
   Oncogene. 2025 Oct 22. doi: 10.1038/s41388-025-03609.
   PubMed     Abstract available
   
   
   
6. WU L, Wu C, He S, Chen Y, et al
   METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.
   Oncogene. 2025 Oct 16. doi: 10.1038/s41388-025-03594.
   PubMed     Abstract available
   
   
   September 2025
7. HUANG L, Zhu M, Chen M, Ying F, et al
   LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.
   Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561.
   PubMed     Abstract available
   
   
   August 2025
8. LI Q, Zhang S, Wang M, Yi Q, et al
   Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
   Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
   PubMed     Abstract available
   
   
   July 2025
9. SHEN C, Cao R, Zhou Q, Zhou T, et al
   LINC00654 promotes ovarian cancer progression by facilitating nuclear export of HuR and stabilizing oncogenic mRNAs.
   Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03500.
   PubMed     Abstract available
   
   
   May 2025
10. SONG C, Lin Y, Cai C, Tao K, et al
    LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
    Oncogene. 2025 May 31. doi: 10.1038/s41388-025-03466.
    PubMed     Abstract available
    
    
    
11. NARAYANA RVL, Gupta R
    Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448.
    PubMed     Abstract available
    
    
    April 2025
12. ZHU Y, Abedini A, Rodriguez GM, McCloskey CW, et al
    Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03387.
    PubMed     Abstract available
    
    
    
13. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    PubMed     Abstract available
    
    
    
14. WAGNER V, Morton M, Dorayappan KDP, Gonzalez A, et al
    Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03382.
    PubMed     Abstract available
    
    
    March 2025
15. ZHAO X, Lai H, Li G, Qin Y, et al
    Rictor orchestrates beta-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer.
    Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03351.
    PubMed     Abstract available
    
    
    
16. WANG J, Yang F, Chen Y, Xing Y, et al
    A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer.
    Oncogene. 2025 Mar 19. doi: 10.1038/s41388-025-03342.
    PubMed     Abstract available
    
    
    
17. FANG D, Chen H, Zhu JY, Wang W, et al
    Editorial Expression of Concern: Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03333.
    PubMed    
    
    
    February 2025
18. XI Q, Kunita A, Ogawa M, Ka M, et al
    Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
    Oncogene. 2025 Feb 24. doi: 10.1038/s41388-025-03312.
    PubMed     Abstract available
    
    
    
19. STEWART J, Krastev DB, Brough R, Zatreanu D, et al
    PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-024-03265.
    PubMed     Abstract available
    
    
    December 2024
20. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    PubMed     Abstract available
    
    
    
21. CHIA ML, Bulat F, Gaunt A, Ros S, et al
    Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.
    Oncogene. 2024 Dec 6. doi: 10.1038/s41388-024-03231.
    PubMed     Abstract available
    
    
    October 2024
22. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    PubMed     Abstract available
    
    
    
23. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    PubMed     Abstract available
    
    
    
24. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    PubMed     Abstract available
    
    
    September 2024
25. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    PubMed     Abstract available
    
    
    
26. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    PubMed     Abstract available
    
    
    August 2024
27. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    PubMed     Abstract available
    
    
    June 2024
28. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    PubMed     Abstract available
    
    
    May 2024
29. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    PubMed     Abstract available
    
    
    April 2024
30. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    PubMed     Abstract available
    
    
    
31. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    PubMed     Abstract available
    
    
    
32. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    PubMed     Abstract available
    
    
    January 2024
33. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    PubMed     Abstract available
    
    
    
34. LIU H, Deng S, Yao X, Liu Y, et al
    Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
    Oncogene. 2024 Jan 15. doi: 10.1038/s41388-024-02940.
    PubMed     Abstract available
    
    
    
35. WU CJ, Pan KF, Chen JQ, Tao Y-, et al
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
    Oncogene. 2024 Jan 4. doi: 10.1038/s41388-023-02918.
    PubMed     Abstract available
    
    
    December 2023
36. YU X, Zhao P, Luo Q, Wu X, et al
    RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-kappaB activation and ovarian cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02910.
    PubMed     Abstract available
    
    
    November 2023
37. AKINJIYAN FA, Ibitoye Z, Zhao P, Shriver LP, et al
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02884.
    PubMed     Abstract available
    
    
    
38. CALLENS C, Rodrigues M, Briaux A, Frouin E, et al
    Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Oncogene. 2023;42:3556-3563.
    PubMed     Abstract available
    
    
    October 2023
39. TAO YP, Zhu HY, Shi QY, Wang CX, et al
    S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.
    Oncogene. 2023 Oct 12. doi: 10.1038/s41388-023-02853.
    PubMed     Abstract available
    
    
    September 2023
40. PETTITT SJ, Shao N, Zatreanu D, Frankum J, et al
    A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant.
    Oncogene. 2023;42:2701-2709.
    PubMed     Abstract available
    
    
    August 2023
41. RAY U, Thirusangu P, Jin L, Xiao Y, et al
    PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Oncogene. 2023 Aug 7. doi: 10.1038/s41388-023-02785.
    PubMed     Abstract available
    
    
    July 2023
42. HEINZL N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, et al
    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Oncogene. 2023 Jul 4. doi: 10.1038/s41388-023-02758.
    PubMed     Abstract available
    
    
    June 2023
43. LI Y, Chen Z, Peng J, Yuan C, et al
    The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Oncogene. 2023 Jun 30. doi: 10.1038/s41388-023-02763.
    PubMed     Abstract available
    
    
    April 2023
44. JIANG Y, Song L, Lin Y, Nowialis P, et al
    ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02679.
    PubMed     Abstract available
    
    
    March 2023
45. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
    PubMed    
    
    
    
46. CHEN K, Yuan X, Wang S, Zheng F, et al
    MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.